Characterization of insulin-like growth factor binding protein-3 (IGFBP- 3) binding to human breast cancer cells: Kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule

Endocrinology

Volumn 140, Issue 3, 1999, Pages 1319-1328

  Yamanaka, Yoshitaka ^a   Fowlkes, John L ^b   Wilson, Elizabeth M ^a   Rosenfeld, Ron G ^a   Oh, Youngman ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; BREAST CANCER; CANCER CELL; CELL TRANSFORMATION; COMPETITIVE INHIBITION; DRUG RECEPTOR BINDING; EPITHELIUM CELL; FIBROBLAST; GLYCOSYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; RECEPTOR AFFINITY; RECEPTOR GENE;

EID: 0032937419     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.3.6566     Document Type: Article

References (61)

1. 1. Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SA, Ramasharma K, Marshall M, Li CH 1989 Insulin-like growth factor-II (IGF-II): a potential autocrine / paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3:1701-1709
2. 2. De Leon DD, Wilson DM, Powers M, Rosenfeld RG 1992 Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth Factors 6:327-336
3. 3. Furlanetto RW, DiCarlo JN 1984 Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res 44:2122-2128
4. 4. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB 1986 Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 46:4613-4619
5. 5. Westley B, May FE 1991 Estrogen-regulated messenger RNAs in human breast cancer cells. Cancer Treat Res 53:259-271
6. 6. Baxter RC, Maitland JE, Raisur RL, Reddel R, Sutherland RL (ed) 1983 High molecular weight somatomedin-C (IGF-I) from T47D human mammary carcinoma cells: immunoreactivity and bioactivity. In: Spencer EM (ed) Insulin-Like Growth Factors/Somatomedins. De Gruyter, Berlin, pp 615-618
7. 7. Cullen KJ, Smith HS, Hill S, Rosen N, Lippman ME 1991 Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 51:4978-4985
8. 8. Paik S 1992 Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22:31-38
9. 9. Puustinen A, Finel M, Virkki M, Wikstrom M 1989 Cytochrome o (bo) is a proton pump in Paracoccus denitrificans and Escherichia coli. FEBS Lett 249:163-167
10. 10. Kita K, Konishi K, Anraku Y 1984 Terminal oxidases of Escherichia coli aerobic respiratory chain. I. Purification and properties of cytochrome b562-o complex from cells in the early exponential phase of aerobic growth. J Biol Chem 259:3368-3374
11. 11 Minghetti KC, Goswitz VC, Gabriel NE, Hill JJ, Barassi CA, Georgiou CD, Chan SI, Gennis RB 1992 Modified, large-scale purification of the cytochrome o complex (bo-type oxidase) of Escherichia coli yields a two heme/one copper terminal oxidase with high specific activity. Biochemistry 31:6917-6924
12. 12. Uno T, Nishimura Y, Tsuboi M, Kita K, Anraku Y 1985 Resonance Raman study of cytochrome b562-o complex, a terminal oxidase of Escherichia coli in its ferric, ferrous, and CO-ligated states. J Biol Chem 260:6755-6760
13. 13. Hata A, Kirino Y, Matsuura K, Itoh S, Hiyama T, Konishi K, Kita K, Anraku Y 1985 Assignment of ESR signals of Escherichia coli terminal oxidase complexes. Biochim Biophys Acta 810:62-72
14. 14. Tsubaki M, Mogi T, Anraku Y, Hori H 1993 Structure of the heme-copper binuclear center of the cytochrome bo complex of Escherichia coli: EPR and Fourier transform infrared spectroscopic studies. Biochemistry 32:6065-6072
15. 15. De Mellow JS, Baxter RC 1988 Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 156:199-204
16. 16. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, Bierich JR 1989 Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I. Endocrinology 125:766-772
17. 17. Liu L, Brinkman A, Blat C, Harel L 1991 IGFBP-1, an insulin like growth factor binding protein, is a cell growth inhibitor. Biochem Biophys Res Commun 174:673-679
18. 18. Ritvos O, Ranta T, Jalkanen J, Suikkari AM, Voutilainen R, Bohn H, Rutanen EM 1988 Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology 122:2150-2157
19. 19. Campbell PG, Novak JF 1991 Insulin-like growth factor binding protein (IGFBP) inhibits IGF action on human osteosarcoma cells. J Cell Physiol 149:293-300
20. 20. Culouscou JM, Shoyab M 1991 Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. Cancer Res 51:2813-2819
21. 21. Delbe J, Blat C, Desauty G, Harel L 1991 Presence of IDF45 (m1GFBP-3) binding sites on chick embryo fibroblasts. Biochem Biophys Res Commun 179:495-501
22. 22. Oh Y, Muller HL, Lamson G, Rosenfeld RG 1993 Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268:14964-14971
23. 23. Cohen P, Lamson G, Okajima T, Rosenfeld RG 1993 Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol 7:380-386
24. 24. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P 1995 The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9:361-367
25. 25 Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB 1987 Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428
26. 26. Fontana JA, Burrows-Mezu A, Clemmons DR, LeRoith D 1991 Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 128:1115-1122
27. 27. Rochefort H 1991 Mechanism of action of high-affinity antiestrogens. An overview. Am J Clin Oncol 14:1-4
28. 28. Wosikowski K, Kung W, Hasmann M, Loser R, Eppenberger U 1993 Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells. Int J Cancer 53:290-297
29. 29. Oh Y, Muller HL, Ng L, Rosenfeld RG 1995 Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 270:13589-13592
30. 30. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG 1996 Insulin-like growth factor binding protein 3 mediates retinoic acid-and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 56:1545-1550
31. 31. Huynh H, Yang X, Pollak M 1996 Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271:1016-1021
32. 32. Hembree JR, Agarwal C, Beard RL, Chandraratna RA, Eckert R 1996 Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor-specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells. Cancer Res 56:1794-1799
33. 33. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N 1995 Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649
34. 34. Oh Y, Muller HL, Pham H, Rosenfeld RG 1993 Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268:26045-26048
35. 35. Rajah R, Valentinis B, Cohen P 1997 Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-betal on programmed cell death through a p53-and IGF-independent mechanism. J Biol Chem 272:12181-12188
36. 36. Liu F, Powell DR, Hintz RL 1990 Characterization of insulin-like growth factor-binding proteins in human serum from patients with chronic renal failure. J Clin Endocrinol Metab 70:6208
37. 37. Spratt SK, Tatsuno GP, Yamanaka MK, Ark BC, Detmer J, Mascarenhas D, Flynn J, Talkington-Verser C, Spencer EM 1990 Cloning and expression of human insulin-like growth factor binding protein 3. Growth Factors 3:63-72
38. 38. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H 1994 Matrix metalloproteinases degrade insulin-like growth factor binding protein-3 in dermal fibroblast cultures. J Biol Chem 269:25742-25746
39. 39. Fowlkes JL, Serra DM, Rosenberg CK, Thrailkill KM 1995 Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis. J Biol Chem 270:27481-27488
40. 40. Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y 1997 Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem 272:30729-30734
41. 41. Munson PJ, Rodbard D 1980 Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239
42. 42. Albiston AL, Herington AC 1990 Cloning and characterization of the growth hormone-dependent insulin-like growth factor binding protein (IGFBP-3) in the rat. Biochem Biophys Res Commun 166:892-897
43. 43. Conover CA 1992 Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism. Endocrinology 130:3191-3199
44. 44. Rechler MM 1993 Insulin-like growth factor binding proteins. Vitam Horm 47:1-114
45. 45. Fowlkes JL, Serra DM 1996 Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3. J Biol Chem 271:14676-14679
46. 46. Arai T, Parker A, Busby Jr W, Clemmons DR 1994 Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem 269:20388-20393
47. 47. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D 1993 Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem 52:196-205
48. 48. Yee D, Favoni RE, Lippman ME, Powell DR 1991 Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat 18:3-10
49. 49. Clemmons DR, Carnacho-Hubner C, Coronado E, Osborne CK 1990 Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology 127:2679-2686
50. 50. Figueroa JA, Yee D 1992 The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer. Breast Cancer Res Treat 22:81-90
51. 51. Jones JI, Gockerman A, Busby Jr WH, Wright G, Clemmons DR 1993 Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 90:10553-10557
52. 52. Martin JL, Ballesteros M, Baxter RC 1992 Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. Endocrinology 131:1703-1710
53. 53. Smith EP, Lu L, Chernausek SD, Klein DJ 1994 Insulin-like growth factor-binding protein-3 (IGFBP-3) concentration in rat Sertoli cell-conditioned medium is regulated by a pathway involving association of IGFBP-3 with cell surface proteoglycans. Endocrinology 135:359-364
54. 54. Andress DL 1995 Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J Biol Chem 270:28289-28296
55. 55. Bar RS, Boes M, Booth BA, Dake BL, Moser DR, Erondu NE 1994 Vascular endothelium, IGFs, IGF binding proteins In: Baxter R, Gluckman P, Rosenfeld R (eds) The Insulin-like Growth Factors and Their Regulatory Proteins. Excerpta Medica, Amsterdam, pp 237-244
56. 56. Booth BA, Boes M, Dake BL, Linhardt RJ, Caldwell EE, Weiler JM, Bar RS 1996 Structure-function relationships in the heparin-binding C-terminal region of insulin-like growth factor binding protein-3. Growth Regul 6:206-213
57. 57. Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, Maack C, Linhardt RJ, Bar K, Caldwell EE, Weiler J, Bar RS 1995 IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul 5:1-17
58. 58. Firth SM, Ganeshprasad U, Baxter RC 1998 Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. J Biol Chem 273:2631-2638
59. 59. Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG 1995 Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res 6:503-512
60. 60. Fowlkes JL, Serra DM 1996 Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3. J Biol Chem 271:14676-14679
61. 61. Leal SM, Liu Q, Huang SS, Huang JS 1997 The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 272:20572-20576